

## DIRECTORS REPORT

To  
The Members,  
**BioGenomics Limited**

Your Directors have pleasure in presenting their Directors Report on the business and operations of your company together with Audited Accounts for the year ended 31 March 2020.

### 1. FINANCIAL RESULTS

The Company's performance during the year ended 31 March 2020 as compared to the previous financial year, is summarized below:

<b>Particular</b>	<b>For the financial year ended 31 March, 2020</b>	<b>For the financial year ended 31 March, 2019</b>
Income	8,65,58,439	155,437,210
Less: Expenses	(42,26,34,762)	(330,787,260)
Profit/ (Loss) before tax	(33,60,76,324)	(175,350,050)
Less: Provision for tax	-	-
Less: Income Tax of earlier years w/off	(79,500)	-
Exception Income	-	-
Exception expenditure	-	-
<b>Profit / (Loss) after Tax</b>	<b>(33,61,55,824)</b>	<b>(175,350,050)</b>



**2. RESERVE& SURPLUS**

During the year under review, the Reserves and Surplus of the Company as on 31 March 2020 stands to be negative i.e. Rs 2,35,20,67,167/-

**3. DIVIDEND:**

The Company is not in a position to pay dividend due to accumulated losses. Your Directors do not recommend any dividend for the year under review.

**4. DISCLOSURE OF INTERNAL FINANCIAL CONTROLS –**

The Internal Financial Controls with reference to financial statements as designed and implemented by the Company are adequate. During the year under review, no material or serious observation has been received from the Statutory Auditors of the Company for inefficiency or inadequacy of such controls.

**5. REVIEW OF BUSINESS OPERATIONS**

During the year under review, the Company has registered a total loss of Rs. 33.62 crores. In this fiscal year, BioGenomics has completed a transformation from engagement in research to revenue generation mode. The Company has received a favorable market response and started small but steady revenue through its unique recombinant enzymes. The company is under process of carrying out clinical trial studies on several of its molecules to prove its safety and efficacy in order to obtain necessary regulatory approvals for commercialization of its regulated products.

**6. SHARE CAPITAL**

The Authorized Share Capital of the Company is 45,00,000 (Forty Five Lakhs ) Equity Shares of Rs.100/- (Rupees Hundred Only) each amounting to Rs.45,00,00,000/- (Forty Five Crores Only) and the Paid-up Share Capital is 42,50,000/- (Eighty Forty Two Lakhs Fifty Thousand Only) Equity Shares amounting to Rs.42,50,00,000/- (Forty Two Crores Fifty Lakhs Only). There was no change in share capital of the Company during the year under review.



## **7. AUDITORS AND REPORTS**

The matters related to Auditors and their Reports are as under:

### **a. Observations of Statutory Auditors on Accounts for the year ended 31<sup>st</sup> March 2020:**

The observations / qualifications / disclaimers made by the Statutory Auditors in their report for the financial year ended 31<sup>st</sup> March 2020 read with the explanatory notes therein are self-explanatory and therefore, do not call for any further explanation or comments from the Board under Section 134(3) of the Companies Act, 2013.

### **b. Re-appointment of auditors:**

Pursuant to the provisions of Section 139 of the Companies Act, 2013 and the Companies (Audit and Auditors) Rules, 2014, M/s. Ford Rhodes Parks & Co. LLP, Chartered Accountants (Registration No. 102860W / W100089), were re-appointed as a statutory auditor of the Company for a term of two years, to hold office from this Annual General Meeting until the conclusion of Annual General Meeting to be held in the year 2022.

Necessary resolution for reappointment of the said Auditors is included in the Notice of AGM for seeking approval of members.

## **8. BOARD OF DIRECTORS & KEY MANAGERIAL PERSONNEL**

During the year under review, there was no change in the Composition of Board of Directors.

The Board of Directors of the Company Comprises of 9 Directors.

Dr. Sanjay Sonar (holding DIN 00208488) Whole- Time Director, Mrs. Archana Krishnan (holding DIN 00208511), Whole – Time Director of the Company is hereby re- appointed for a further term of 3 years from 1<sup>st</sup> July, 2020 to 30<sup>th</sup> June, 2023 and Mr. Ranjan Mogre (holding DIN 01756856), Independent Director and Mr. Vijayanand Ramchandra Bhate ( DIN No. 05238248), Independent Director of the Company will be re –appointed for the term of five years at the ensuing Annual General Meeting and being eligible, offer themselves for re appointment. The Directors place on record their appreciation for their contribution in guiding and supporting the Company's Business and operations during their tenure as Directors and recommend their offer of reappointment for consideration in the AGM.



It is further confirmed that none of the above directors are disqualified under section 164(2) of the Companies Act, 2013.

**Declarations by Independent Directors:**

The Company has received declarations form all the Independent Directors under Section 149(6) of the Companies Act, 2013 confirming their independence vis-à-vis the Company

**9. BOARD MEETINGS, AUDIT COMMITTEE MEETINGS AND ANNUAL GENERAL MEETING**

During the year under review 6 Board meetings were held:

SR No.	Date of the Meeting	Place of the Meeting
1.	15 <sup>th</sup> May, 2019	Chennai
2.	23 <sup>rd</sup> June, 2019	Oman
3.	07 <sup>th</sup> Sept, 2019	Oman
4.	8 <sup>th</sup> Nov, 2019	Mumbai
5.	23 <sup>rd</sup> January, 2020	Mumbai
6.	24 <sup>th</sup> February, 2020	Mumbai

The Annual General Meeting (AGM) of the Company was held on 30<sup>th</sup> September 2019 and the Extra Ordinary General Meeting of the Company was held on 24<sup>th</sup> February, 2020 and 31<sup>st</sup> March, 2020.

**AUDIT COMMITTEE:**

The Audit Committee of Directors was constituted pursuant to the provisions of Section 177 of the Companies Act, 2013. The composition of the Audit Committee is in conformity with the provisions of the said section. During the year 4 Audit Committee Meeting were held :

SR No.	Date of the Meeting	Place of the Meeting
1.	23 <sup>rd</sup> June, 2019	Oman
2.	07 <sup>th</sup> Sept, 2019	Oman
3.	08 <sup>th</sup> Nov, 2019	Mumbai
4.	23 <sup>rd</sup> Jan, 2020	Mumbai

During the year under review, the Board of Directors of the Company had accepted all the recommendations of the Committee.



**Nomination and Remuneration Committee:**

The Nomination and Remuneration Committee of Directors as constituted by the Board of Directors of the Company in accordance with the requirements of Section 178 of the Act.

**10. MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY:**

Except as disclosed elsewhere in this report, no material changes and commitments which could affect the Company's financial position have occurred between the end of the financial year of the Company and date of this report.

**11. RISK MANAGEMENT POLICY:**

The Board of Directors of the Company has not designed any Risk Management Policy. However, the Company has in place mechanism to identify, assess, monitor and mitigate various risks to key business objectives. Major risks identified by the businesses and functions are systematically addressed through mitigating actions on a continuing basis

**12. ANNUAL EVALUATION OF DIRECTORS, COMMITTEE AND BOARD.**

The Board has carried out an annual performance evaluation of its own performance, and of the directors individually, as well as the evaluation of all the committees' i.e Audit, Nomination and Remuneration. The Board adopted a formal evaluation mechanism for evaluating its performance and as well as that of its Committees and individual Directors, including the Chairman of the Board the exercise was carried out by feedback survey from each directors covering Board functioning such as composition of Board and its Committees, experience and competencies, governance issues etc. Separate Exercise was carried out to evaluate the performance of individual directors including the Chairman of the Board who were evaluated on paramaters such as attendance, contribution at the meeting etc.



### **13. DIRECTORS RESPONSIBILITY STATEMENT**

In terms of Section 134(5) of the Companies Act, 2013, the Directors state that:

- (a) in the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- (b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for the year under review;
- (c) the directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013, for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- (d) the directors have prepared the annual accounts on a going concern basis; and
- (e) the directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.
- (f) the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

### **14. REPORT ON PERFORMANCE OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURE COMPANIES:**

During the year under review, your Company did not have any subsidiary, associate and joint venture company.

### **15. DEPOSITS**

The Company has not accepted or renewed any amount falling within the purview of provisions of Section 73 of the Companies Act 2013 ("the Act") read with the Companies (Acceptance of Deposit) Rules, 2014 during the year under review. Hence, the requirement for furnishing of details relating to deposits covered under Chapter V of the Act or the details of deposits which are not in compliance with the Chapter V of the Act is not applicable.



**16. PARTICULAR OF CONTRACTS OR ARRANGEMENT WITH RELATED PARTIES**

All contracts/ arrangements/ transactions, that were entered into during the financial year were on an arm's length basis and were in the ordinary course of business.

During the year the Company has not entered into any material transactions hence the form AOC-2 regarding particulars of contract or arrangement with the related parties as referred in section 188(1) of the Companies Act, 2013 is not required to be annexed herewith.

**17. PARTICULARS OF LOANS, GUARANTEES AND INVESTMENTS:**

The Company has not made any loans, guarantees and investments covered under section 186 of the Act.

**18. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO**

**i. Conservation of energy:**

There were numerous energy saving measures undertaken by the company in both the processes and the equipment's used, as a result of which the factory is expected to run in a more efficient and environmentally friendly manner.

**ii. Technology Absorption:**

**Research and development:**

Specific areas in which the Company has put in research and development efforts are:

- Unified platform technology
- High production yields
- Stable production during fermentations
- Novel protein refolding procedures
- A novel purification strategy which provides high purity and high yields.

**Benefits derived as a result of the above research and development:**

Based on the R&D activities of the company, commercial production and submission of samples to various potential buyers is successfully completed.



**Future plans for action:**

1. Completion of clinical trial studies of regulated products.
2. Commercialization and large scale production of regulated and unregulated products after completion of clinical trial studies of regulated products.
3. Development of recombinant chimeric monoclonal antibodies based on mammalian cell culture.

**Technology absorption, adoption and innovation:**

The R&D center carries out developmental activities in several areas such as import substitution for raw materials, batch cycle time reduction as also line extensions of existing products. The Company has fully absorbed the technology developed as a result of its own R&D activity.

Benefits to be derived as a result of the above:

1. No cost of technology
2. Completely indigenous technology with very high potential for future product developments.

**19. FOREIGN EXCHANGE EARNINGS AND OUTGO:**

During the year, your Company earned foreign exchange revenue of Rs. 3,67,26,119/-and incurred foreign exchange expenditure of Rs. 4,70,114/-

**20. DISCLOSURE OF ORDERS PASSED BY REGULATORS OR COURTS OR TRIBUNAL**

No orders have been passed by any Regulator or Court or Tribunal which can have impact on the going concern status and the Company's operations in future.

**21. EXTRACT OF ANNUAL RETURN:**

Pursuant to the provisions of Section 134(3)(a) of the Companies Act, 2013, Extract of the Annual Return for the financial year ended 31<sup>st</sup> March 2020 made under the provisions of Section 92(3) of the Act is attached as Annexure I which forms part of this Report.



## **22. DISCLOSURE ABOUT ESOP AND SWEAT EQUITY SHARES**

No employee was granted shares (under ESOPs and Sweat Equity Scheme), during the year 2019-20.

## **23. PARTICULARS OF EMPLOYEES**

The information required pursuant to section 197 read with rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 in respect of remuneration to the Chairman & Managing Director & Whole Time Directors/ Joint Managing Director is disclosed in the Annexure MGT-9

In the year under review, no employee of the Company has drawn remuneration of Rs. Eight Lakh and Fifty Thousand per month or Rs. One Crore and two lakhs rupees per annum.

In terms of Section 136 of the Act, the reports and accounts are being sent to the members and others entitled thereto, the information on employees' particulars which is available for inspection by the members at the Registered Office of the Company during business hours on working days of the company up to the date of ensuing Annual General Meeting. If any member is interested in inspecting the same, such member may write to the Company in advance.

## **24. VIGIL MECHANISM**

The Vigil Mechanism as envisaged in the Companies Act, 2013, the Rules prescribed thereunder is implemented through the Company's Whistle Blower Policy to enable the Directors and employees of the Company to report genuine concerns, to provide for adequate safeguards against victimization of persons who use such mechanism.

## **25. DISCLOSURE UNDER SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION & REDRESSAL) ACT, 2013.**

Your Company has in place of Sexual Harassment Policy for prevention of Sexual Harassment in line with the "The Sexual Harassment of Women at workplace (Prevention and Prohibition and Redressal) Act & Rules, 2013. To create a robust framework for this policy dissemination, the Company from time to time undertakes awareness creation and periodic reiteration among all executives. During the year Company has not received any complaints.



**ACKNOWLEDGEMENTS AND APPRECIATION:**


Your Directors wish to express their grateful appreciation for the assistance and cooperation received from Bankers, Customers and Suppliers.

Cordial relations prevailed during the year with all the employees. Your Directors wish to place on record their deep sense of appreciation of the valuable work done and co-operation extended by them at all levels.

Your Directors also wish to express their gratitude to investors for the continued faith reposed by them in the Company.

**For and on behalf of the Board**

**Biogenomics Limited**



**Dr. Sanjay sonar**

**Whole Time Director  
DIN: 00208488**

**Address:905/B, Princeton,  
Hiranandani Estate, Thane West,  
Thane-400607**

Place: Thane

Date:7 August 2020



**Rajmal Parakh**

**Managing Director  
DIN: 00147968**

**Add: P O Box 3168, Muscat., Postal  
Code 112, Sultanate Of Oman, 112,  
Oman**

**Registered Office**

**1-A, Valliamal Road,  
Opp. Seventh Day Adventist School, Vepery,  
Chennai-600007**

**CIN:U24234TN2002PLC048821**

**Tel No: 022-41617181 Fax No. 022-41617199**

**Mail [secretarial@biogenomics.co.in](mailto:secretarial@biogenomics.co.in)**

**website<http://www.biogenomics.co.in/>**

**Form No. MGT-9**  
**Extract of Annual Return as on the financial year ended on 31<sup>st</sup> March 2020**  
**[Pursuant to section 92(3) and Rule 12(1) of the**  
**Companies (Mangement and Administration) Rules, 2014]**

**I. REGISTRATION AND OTHER DETAILS**

i.	CIN	U24234TN2002PLC048821
ii.	Registration Date	24/04/2002
iii.	Name of the Company	Biogenomics limited
iv.	Category / Sub-Category of the Company	Company limited by shares
v.	Address of the Registered office and contact details	1-A, Valliamal Road, Opp. Seventh Day Adventist School, Vepery, Chennai-600007
vi.	Whether listed company (Yes / No)	No
vii.	Name, Address and Contact details of Registrar and Transfer Agent, if any	Sharex Dynamic (India) Pvt. Ltd. C-101, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai - 400 083.   T: 2851 5606/ 5644 Web: <a href="http://www.sharexindia.com">http://www.sharexindia.com</a>

**II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY**

All the business activities contributing 10% or more of the total turnover of the Company, on standalone basis, are as under:

Sl. No.	Name and Description of main products / services	NIC Code of the Product/ service	% to total turnover of the Company
1.	Proteins, enzymes and biologics	21001	30%

**III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES**

Sl. No.	Name and Address of the Company	CIN/GLN	Holding/ Subsidiary/ Associate	% of shares held	Applicable Section
1.	MB Holding Mauritius Limited, Mauritius	NA	Holding Company	56.97	2 (46)



**IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)**

**i) Category-wise Share Holding**

Category of shareholders	No. of Shares held at the beginning of the year (As on 01.04.2019)				No. of Shares held at the end of the year (As on 31.03.2020)				% change during the year
	Demat	Physical	Total	% of total shares	Demat	Physical	Total	% of total shares	
<b>A. Promoters &amp; Promoter Group</b>									
<b>(1) Indian</b>									
Individual/HUF	0	853,025	853,025	20.07	0	853,025	853,025	20.07	0.00
Central Govt.	0	0	0	0.00	0	0	0	0.00	0.00
State Govt.(s)	0	0	0	0.00	0	0	0	0.00	0.00
Bodies Corp.	0	0	0	0.00	0	0	00	0.00	0.00
Banks / FI	0	0	0	0.00	0	0	0	0.00	0.00
Any Other	0	0	0	0.00	0	0	0	0.00	0.00
Sub-total (A)(1)	0								
<b>(2) Foreign</b>									
a) NRIs - Individuals	0	650,533	650,533	15.31	0	650,533	650,533	15.31	0.00
b) Other – Individuals	0	325,265	325,265	7.65	0	325,265	325,265	7.65	0.00
Bodies Corp.	0	2,421,177	2,421,177	56.97	0	2,421,177	2,421,177	56.97	0.00
Banks / FI	0	0	0	0.00	0	0	0	0.00	0.00
Any Other	0	0	0	0.00	0	0	0	0.00	0.00
Sub-total (A)(2)	0	0	0	0.00	0	0	0	0.00	0.00
Total shareholding of Promoter (A) = (A)(1)+(A)(2)	0								



Category of shareholders	No. of Shares held at the beginning of the year (As on 01.04.2019)				No. of Shares held at the end of the year (As on 31.03.2020)				% change during the year
	Demat	Physical	Total	% of total shares	Demat	Physical	Total	% of total shares	
<b>B. Public Shareholding</b>									
1. Institutions	0	0	0	0.00	0	0	0	0.00	0.00
a) Mutual Funds	0	0	0	0.00	0	0	0	0.00	0.00
b) Banks / FI	0	0	0	0.00	0	0	0	0.00	0.00
c) Central Govt.	0	0	0	0.00	0	0	0	0.00	0.00
d) State Govt.(s)	0	0	0	0.00	0	0	0	0.00	0.00
e) Venture Capital Funds	0	0	0	0.00	0	0	0	0.00	0.00
f) Insurance Companies	0	0	0	0.00	0	0	0	0.00	0.00
g) FII's	0	0	0	0.00	0	0	0	0.00	0.00
h) Foreign Venture Capital Funds	0	0	0	0.00	0	0	0	0.00	0.00
i) Others - Qualified Foreign Investor	0	0	0	0.00	0	0	0	0.00	0.00
<b>Sub-total (B)(1)</b>	0	0	0	0.00	0	0	0	0.00	0.00
2. Non-Institutions									
a) Bodies Corp.	0	0	0	0.00	0	0	0	0.00	0.00
i) Indian	0	0	0	0.00	0	0	0	0.00	0.00
ii) Overseas	0	0	0	0.00	0	0	0	0.00	0.00
b) Individuals	0	0	0	0.00	0	0	0	0.00	0.00
i) Individual shareholders holding nominal share capital up to Rs. 1 lakh	0	0	0	0.00	0	0	0	0.00	0.00
ii) Individual shareholders holding nominal share capital in excess of Rs. 1 lakh	0	0	0	0.00	0	0	0	0.00	0.00



Category of shareholders	No. of Shares held at the beginning of the year (As on 01.04.2019)				No. of Shares held at the end of the year (As on 31.03.2020)				% change during the year
	Demat	Physical	Total	% of total shares	Demat	Physical	Total	% of total shares	
c) Others (specify)	0	0	0	0.00	0	0	0	0.00	0.00
Non-Resident Individuals	0	0	0	0.00	0	0	0	0.00	0.00
Clearing Members	0	0	0	0.00	0	0	0	0.00	0.00
Trust	0	0	0	0.00	0	0	0	0.00	0.00
Sub-total (B)(2)	0	0	0	0.00	0	0	0	0.00	0.00
Total Public Shareholding (B) = (B)(1)+(B)(2)	0	0	0	0.00	0	0	0	0.00	0.00
C. Shares held by Custodian for GDRs & ADRs	0	0	0	0.00	0	0	0	0.00	0.00
Grand Total (A+B+C)	0	4,250,000	4,250,000	100.00	0	4,250,000	4,250,000	100.00	0.00



(ii) Shareholding of Promoters

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year (As on 01.04.2019)			Shareholding at the end of the year (As on 31.03.2020)			% change in share-holding during the year
		No. of Shares	% of total Shares of the Company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the Company	% of Shares Pledged / encumbered to total shares	
1.	MB Holdings Mauritius Limited, Mauritius	2,421,177	56.97	00	2,421,177	56.97	00	
2.	Rajmal Parakh	650,533	15.31	00	650,533	15.31	00	
3.	Sanjay Sonar	342,325	8.05	00	342,325	8.05	00	
4.	Archana Krishnan	342,325	8.05	00	342,325	8.05	00	
5.	Suleiman Harthy	325,265	7.65	00	325,265	7.65	00	
6.	Rajeshree Deshpande	122,451	2.88	00	122,451	2.88	00	
7.	Aparna Kulkani	45,924	1.08	00	45,924	1.08	00	
	Total shareholding of Promoter	4,250,000	100	00	4,250,000	100	00	



(iii) Change in Promoters' Shareholding (please specify, if there is no change)

Sl. No.	Particulars	Shareholding at the beginning of the year (As on 01.04.2019)		Cumulative Shareholding during the year (As on 31.03.2020)	
		No. of Shares	% of total Shares of the Company	No. of Shares	% of total Shares of the Company*
	NO CHANGE				

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs)

Sl. No.	For Each of the Top 10 Shareholders	Shareholding at the beginning of the year		Shareholding at the end of the year	
		No. of Shares	% of total Shares of the Company	No. of Shares	% of total Shares of the Company
	NOT APPLICABLE				

(v) Shareholding of Directors and Key Managerial Personnel:

Sl. No.	For each of the directors and KMP	Shareholding at the beginning of the year (As on 01.04.2019)		Cumulative Shareholding during the year (As on 31.03.2020)	
		No. of Shares	% of total Shares of the Company	No. of Shares	% of total Shares of the Company
1.	Rajmal Parakh	650,533	15.31	650,533	15.31
2.	Sanjay Sonar	342,325	8.05	342,325	8.05
3.	Archana Krishnan	342,325	8.05	342,325	8.05
4.	Ranjan Mogre	00	00	00	00
5.	Mohamed Ali Mohamed Al	00	00	00	00



Sl. No.	For each of the directors and KMP	Shareholding at the beginning of the year (As on 01.04.2019)		Cumulative Shareholding during the year (As on 31.03.2020)	
		No. of Shares	% of total Shares of the Company	No. of Shares	% of total Shares of the Company
	Barwani				
6.	Usama Mohamed Ali Barwani	00	00	00	00
7.	Sushil kumar Srivastava	00	00	00	00
8.	Vijayanand Bhate	00	00	00	00
9.	Suleiman Harthy	00	00	00	00
10.	Abhishek Deshpande	00	00	00	00

## V. INDEBTEDNESS

Indebtedness of the Company including interest outstanding / accrued but not due for payment

Particulars	Secured Loans excluding deposits (Rs.)	Unsecured Loans (Rs.)	Deposits (Rs.)	Total Indebtedness (Rs.)
Indebtedness at the beginning of the financial year	00	1,754,075,570	00	1,754,075,570
i) Principal Amount	00	1,749,320,319	00	1,749,320,319
ii) Interest due but not paid	00	4,755,251	00	4,755,251
iii) Interest accrued but not due	00	00	00	00
<b>Total (i+ii+iii)</b>	<b>00</b>	<b>1,754,075,570</b>	<b>00</b>	<b>1,754,075,570</b>
Change in Indebtedness during the financial year	00	16,90,51,156	00	16,90,51,156



<b>Addition</b>	00	16,90,51,156	00	16,90,51,156
<b>Reduction</b>	00	00	00	00
<b>Net Change</b>	00	16,90,51,156	00	16,90,51,156
<b>Indebtedness at the end of the financial year</b>	00	1,92,31,26,726	00	1,92,31,26,726
<b>i) Principal Amount</b>	00	1,91,79,44,246	00	1,91,79,44,246
<b>ii) Interest due but not paid</b>	00	51,82,480	00	51,82,480
<b>iii) Interest accrued but not due</b>	00	00	00	00
<b>Total (i+ii+iii)</b>	<b>00</b>	<b>1,92,31,26,726</b>	<b>00</b>	<b>1,92,31,26,726</b>

## VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

### A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

Sr. No.	Particulars of Remuneration	MD / WTD / MANAGER			Total Amount
		Rajmal Parakh Managing Director	Sanjay Sonar Whole-time Director	Archana Krishnan Whole-time Director	
1.	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	00	66,00,000	66,00,000	1,32,00,000
2.	Stock Option	00	00	00	00
3.	Sweat Equity	00	00	00	00
4.	Commission - as % of profit - others, specify...	00	00	00	00
5.	Others, please specify (Reimbursement of Expenses)	00	00	00	00
	<b>Total (A)</b>	<b>00</b>	<b>66,00,000</b>	<b>66,00,000</b>	<b>1,32,00,000</b>



**C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD / MANAGER / WTD:**

Sl. No.	Particulars of Remuneration	Key Managerial Personnel			Total Amount
		Chief Executive Officer –	Company Secretary- Pooja Somani	CFO- Abhishek Deshpande	
1.	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	00	415,531	63,87,972	6,803,503
2.	Stock Option	00	00	00	00
3.	Sweat Equity	00	00	00	00
4.	Commission - as % of profit - others, specify...	00	00	00	00
5.	Others, please specify (Reimbursement of Expenses)	00	00	00	00
	<b>Total</b>	<b>00</b>	<b>415,531</b>	<b>63,87,972</b>	<b>6,803,503</b>




**PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:**

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority [RD /NCLT/ COURT]	Appeal made, if any (give Details)
<b>A. COMPANY</b>					
Penalty	NA	NA	NA	NA	NA
Punishment	NA	NA	NA	NA	NA
Compounding	NA	NA	NA	NA	NA
<b>B. DIRECTORS</b>					
Penalty	NA	NA	NA	NA	NA
Punishment	NA	NA	NA	NA	NA
Compounding	NA	NA	NA	NA	NA
<b>C. OTHER OFFICERS IN DEFAULT</b>					
Penalty	NA	NA	NA	NA	NA
Punishment	NA	NA	NA	NA	NA
Compounding	NA	NA	NA	NA	NA

**For and on behalf of the Board**

**Biogenomics Limited**




**Dr. Sanjay sonar**

**Whole Time Director  
DIN: 00208488**

**Address:905/B, Princeton,  
Hiranandani Estate, Thane West,  
Thane-400607**

Place: Thane

Date:7 August 2020



**Rajmal Parakh**

**Managing Director  
DIN: 00147968**

**Add: P O Box 3168, Muscat., Postal  
Code 112, Sultanate Of Oman, 112,  
Oman**